INTENDED USE
The Malaria Rapid Test is a lateral flow chromatographic
immunoassay for the simultaneous detection and differentiation of Plasmodium falciparum (Pf) antigen and P. vivax, P. ovale, or P. Malariea antigen in whole blood. This device is intended to be used as a screening test and as an aid in the diagnosis of infection with Plasmodium. Any reactive specimen with the Malaria Rapid Test must be confirmed with alternative testing method(s) and clinical findings.
SUMMARY AND EXPLANATION OF THE TEST
Malaria is a mosquito-borne, hemolytic, febrile illness that infects over 200 million people and kills more than 1 million people per year. It is caused by four species of Plasmodium: P. falciparum, P. vivax, P.ovale, and P. malariae. These plasmodia all infect and destroy human erythrocytes, producing chills, fever, anemia, and splenomegaly. P. falciparum causes more sever disease than the other plasmodial species and accounts for most malaria deaths. P. falciparum and P. vivax are the most common pathogens, however, there is considerable geographic variation in species distribution1. Traditionally, malaria is diagnosed by the demonstration of the organisms on Giemsa stained smears of peripheral blood, and the different species of plasmodium are distinguished by their appearance in infected erythrocytes1. The technique is capable of accurate and reliable diagnosis, but only when performed by skilled microscopists using defined protocols2, which presents major obstacles for the remote and poor areas of the world.
The Malaria Rapid Test is developed for solving these above obstacles. It detects the antibodies generated in serum or plasma in response to the infection of plasmodium. Utilizing the Pf. specific antigen (HRP-II) and pan-malaria antigen (aldolase), the test enables simultaneous detection and differentiation of the infection of P.falciparum and or P. vivax, ovale, and malariae3-5, by untrained or minimally skilled personnel, without laboratory equipment.
SARS-CoV-2 Rapid Antigen Test kit Colloidal Gold Method Medical Simple Rapid Convenient Sensitivity : 98.4% Specificity : 98.1% Test Time : 10-15min
For in vitro qualitative detect of Covid-19 antigen in nasal(NS) swab specimens directly from individuals who are suspected of COVID-19 by their healthcare provider within the first 5 days of the onset of the symptoms. This test is only provided for use by clinical laboratories or to healthcare workers for point-of-care testing, and not for at home testing. 1.Easy to collect samples simple operation without professional equipment. 2.The test results are available in 15 minutes, and the test results are clearly visible. 3.Convenient transportation and low price, higher accuracy. 4.Suitable for large-scale rapid screening. Shelf life: 24 Months Test Result time: 10 Mins Packing: 25 Pieces per Box
Angiten-COVID-19 Virus Test Kit (Colloidal Gold) Quantity of box: 25 persons/box Brand: Easysweet NMPA (National Medical Products Administration): Approved CE: with CE mark BfArM: listed Test Method: Antigen Test Result Time: 10-15 mins Sample Type: Nasal Swab Sensitivity: 96.70% Specificity: 100% Accuracy: 98.94% Shelf Life: 24 months Storage Temperature: 2-30 Degree Celsius Country of Origin: Made in China Additional Information: Production Capacity: 1 million Delivery Time: 10-15 days Packaging Details: 25 tests in a pack, 40packs/ carton Angiten-COVID-19 Virus Test Kit is an in vitro diagnostic rapid test for the qualitative detection of SARS-CoV-2 antigen (Ag) in human nasopharyngeal swab specimens from individuals who meet COVID-19clinical and / or epidemiological criteria. It can be used by professional only. Price and Minumum Quantity Price FOB in USD: NegotiableMinimum Order Qty: 10000 Production Capacity: 1000000Packaging: 25 Persons/box Sample: Available. Sample Cost Born By Buyer Product Model And Origin Brand: Easysweet HS Code: 3822009020 Standards: Ce Competitive Advantages Best price with shortest delivery time Best price with shortest delivery time Best price with shortest delivery time Best price with shortest delivery time Other Details Angiten-covid-19 virus test kit (colloidal gold) Angiten-covid-19 virus test kit (colloidal gold) Angiten-covid-19 virus test kit (colloidal gold) Angiten-covid-19 virus test kit (colloidal gold)
Malaria Antigen PF/PV Card Test
Covid-19 Self Test Kit We are the authorized first vendor of ADTech! KFDA CE approved, FDA Pending Price : Negotiable Pre-Clinical Test Report Accuracy - In total samples 93.3% (14/15) - In positive samples 91.7% (11/12) 1. Pre-Clinical Test summary 1) Pre-clinical test is fulfilled by Domestic large clinical laboratory with ADTech COVID-19 IgM/IgG RAPID KIT 2) Tests are made by total 15 samples with 12 positive and 3 negative samples 3) Clinical Laboratory tested the sample with Immunofluorescence Analysis 2. Pre-clinical test result 1) Samples were tested by ADTech COVID-19 IgM/IgG RAPID KIT 2) Test result by ADTechs RAPID KIT - 4 negatives and 11 positives results in 15 samples 3) Comparison between Immunofluorescence analysis and ADTechs RAPID KIT - 14 test results are same(including negative and positive results) - 1 samples test result are different(Positive Negative by ADTech
Saliva Test Kit Painless testing plastic disposable Ag Rapid Detection Kit
Antibody Test Kits Hot Sale Medical Diagnostic Antigen Antibody Rapid Test Kits
Beright brand, oral fluid with CE1434 and self-testing certificate. Stock EU, shipping 3-6 days with DHL economy to any country of Europe.
Access Bio Care Start Covid-19 Rapid Antigen Test Kit Product Details: Number of Reactions(Preps) per Kit : 1 Brand : Access Bio Test Method : Antigen Test Result Time (Rapid Kits) : 10 min Sample Type ; Nasal Swab Packaging Size : 20 Test Kits/Box Packaging Type : Box The CareStart COVID-19 Antigen test is a lateral flow immunochromatographic assay intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in nasopharyngeal or anterior nasal swab specimens directly collected from individuals who are either suspected of COVID-19 by their healthcare provider within first five days of symptom onset, or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 48 hours between
